Clinical Trials in the EU / 2025-523757-33-00
Authorised, recruiting
Phase II
A Phase 2, Multicenter, Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Ublituximab Administered at Various Injection Sites and Relative Bioavailability via Autoinjector Device versus Syringe in Patients with Multiple Sclerosis
2025-523757-33-00 · tracked via the Priya Life Science EU tracker
Condition studied
multiple sclerosis
Investigational medicinal product(s)
Ublituximab
Eligibility
Primary endpoint
Incidence of treatment emergent adverse events (TEAE)
Endpoint detail
Incidence of TEAE
Official registry record
This page summarises publicly available CTIS data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View 2025-523757-33-00 on CTIS ↗ ← All trials in the EU